Annovis Bio (NYSE: ANVS) has promoted Cheng Fang, Ph.D., to chief scientific officer, the company announced. Fang, who joined Annovis in 2021 and most recently served as senior vice president of research and development, will oversee scientific strategy and research operations across the company’s Alzheimer’s disease (AD) and Parkinson’s disease (PD) programs. His responsibilities include translational science, clinical development, biomarker strategy and regulatory interactions.
The promotion comes at a critical time as Annovis advances its lead drug candidate, buntanetap, toward top-line data from its pivotal Phase 3 Alzheimer’s disease study and a subsequent New Drug Application (NDA) submission. According to the company, Fang has played a key role in advancing clinical development efforts and will lead scientific strategy through these upcoming clinical and regulatory milestones. The full press release can be accessed at https://ibn.fm/c9jdt.
Annovis Bio, headquartered in Malvern, Pennsylvania, is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases. Its lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients.
The appointment underscores Annovis’ commitment to advancing its pipeline and preparing for regulatory submissions. As the company approaches key data readouts, Fang’s leadership will be instrumental in interpreting results and guiding the next steps. More information about Annovis Bio is available at www.annovisbio.com.
